| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/29/2009 | CN100482276C Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 04/29/2009 | CN100482225C Novel heterocyclic compounds which are active as inhibitors of beta-lactamases |
| 04/29/2009 | CN100482219C Novel compounds, pharmaceutical compositions containing same, and methods of use for same |
| 04/29/2009 | CN100482095C Injure preventing agent for forcedly changing feather and method for forcedly changing feather |
| 04/28/2009 | US7524975 Peroxisome proliferator activated receptor ligand and process for producing the same |
| 04/28/2009 | US7524969 Cardiovascular disorders; anticancer agents; antidiabetic agents; dietetics |
| 04/28/2009 | US7524957 Compounds effecting glucokinase |
| 04/28/2009 | US7524936 labeled monoclonal or polyclonal antibodies that preferentially binds oxidoreductase enzyme polypeptides, proteins, fragments, domain peptides or amino acid sequences having replacements, capable of superoxide production |
| 04/28/2009 | US7524930 polypeptides consisting of amino acid sequences or peptide fragments and drug carriers, used for inducing and/or activating human leukocyte antigens (HLA-A2)-restricted tumor-specific cytotoxic T lymphocytes; anticancer vaccines |
| 04/28/2009 | US7524883 Eponemycin and epoxomicin analogs and uses thereof |
| 04/28/2009 | US7524875 Polyether with glycerol backbone; capable of being labeled |
| 04/28/2009 | US7524861 Process for the preparation of a hydrate of an anthranilic acid derivative |
| 04/28/2009 | US7524858 Substituted pyrroline kinase inhibitors |
| 04/28/2009 | US7524857 Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents |
| 04/28/2009 | US7524852 Bicyclic pyrimidine derivatives |
| 04/28/2009 | US7524850 1-{1-[4-(6-hydroxy-5-isobutyl-3-phenylpyrazin-2-yl)benzyl]piperidin-4-yl}-1,3-dihydro-2H-benzimidazol-2-one; serine/threonine protein kinase; antiproliferative |
| 04/28/2009 | US7524847 Inhibit Dipeptidyl peptidase-IV; 7-(2-Butynyl)-3-methyl-3,7-dihydropurine-2,6-dione; suppress degradation of Glucagon-Like Peptide-1; enhance action of incretin; facilitate insulin secretion from pancreatic beta -cells due to glucose stimulus; postchallenge hyperglycemia, improved oral glucose tolerance |
| 04/28/2009 | US7524843 N-methyl-N-(1-methyl-1H-indol-3-ylmethyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide as an enzyme inhibitor for both Fab I and Fab K which are used in the biosynthesis of fatty acids; enoyl-acyl-carrier protein renamed Fab 1; bactericides; fungicides; Staphylococcus aureus; antibiotics |
| 04/28/2009 | US7524841 4,4-disubstituted piperidine derivatives having CCR3 antagonism |
| 04/28/2009 | US7524828 Immunostimulatory nucleic acid molecules |
| 04/28/2009 | US7524820 Administering one or more enzyme inhibitors, selected from tripeptides, tetrapeptides and pentapeptides, to inhibit neucrosis factor kappa Beta mediated inflammatory cytokine release |
| 04/28/2009 | US7524815 Bovine or colostrum; milk, yogurt, curd, cheese, fermented milks, milk-based fermented products, ice creams, fermented cereal-based products, milk-based powders, infant formula, pet food; Osteoporosis, Paget's Disease, hypercalcemia, bone loss from arthritis, necrosis, or periodontal disease |
| 04/28/2009 | US7524679 Methods for culturing human lung mast cells and uses thereof |
| 04/28/2009 | US7524649 Chimeric polypeptide having a modified binding domain of growth hormone linked to a receptor binding domain of growth hormone receptor; treating giantism; acromegaly; cancer diabetic retinopathy; diabetic nephropathy, diabetic complications and any disease of growth hormone excess |
| 04/28/2009 | US7524643 Nucleotide sequences coding voltage gated calcium channels (VGCC) for treating neurological and cardiovascular disorders; anticonvulsant |
| 04/28/2009 | US7524509 Proteosome-liposaccharide vaccine adjuvant |
| 04/28/2009 | US7524502 Modified anti-TNF alpha antibody |
| 04/28/2009 | US7524500 Method of stimulating stem cells |
| 04/28/2009 | US7524488 Interleukin-18 mutants |
| 04/28/2009 | US7524484 Delivery of diphenhydramine through an inhalation route |
| 04/28/2009 | CA2472954C Aza-arylpiperazines |
| 04/28/2009 | CA2429793C Interferon therapeutic effect enhancer |
| 04/28/2009 | CA2425314C Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 04/28/2009 | CA2416311C 16alpha-methyl or ethyl substituted estrogens |
| 04/28/2009 | CA2380074C Novel amide derivatives |
| 04/28/2009 | CA2336783C Novel 2,3,3a,4,9,9a hexahydro-8-hydroxy-1h-benz[f]indoles, a method for the production thereof, and their use as medicaments |
| 04/28/2009 | CA2334761C Composition comprising .beta.-hydroxy-.beta.-methylbutyric acid and at least one amino acid and methods of use |
| 04/28/2009 | CA2273328C 5-cyclo indole compounds as 5-ht1d receptor ligands |
| 04/28/2009 | CA2222964C Oxygen activatable formulations for disinfection or sterilization |
| 04/23/2009 | WO2009052484A2 Predicting responsiveness to cancer therapeutics |
| 04/23/2009 | WO2009052342A1 Combination therapy for reducing side effects using cannabinoid receptor ligands |
| 04/23/2009 | WO2009051223A1 Pharmaceutical composition for treatment of cataract |
| 04/23/2009 | WO2009051210A1 Method for producing pyrazole fused ring derivative |
| 04/23/2009 | WO2009051151A1 Therapeutic agent for trpv1-mediated disease |
| 04/23/2009 | WO2009051112A1 Amide compounds and use of the same |
| 04/23/2009 | WO2009051078A1 Therapeutic gene expression system |
| 04/23/2009 | WO2009050136A2 Glucocorticoid receptor antagonists such as mifepristone for treating cushing' s syndrome |
| 04/23/2009 | WO2009049422A1 Compositions and methods for enhancing enzyme activity in gaucher, gm1 -gangliosidosis/morquio b disease. and parkinson's disease |
| 04/23/2009 | WO2009049421A1 Compositions and methods for enhancing enzyme activity in gaucher, gm1-gangliosidosis/morquio b disease, and parkinson's disease |
| 04/23/2009 | WO2009018511A3 Alpha7 nachr agonists for treating or preventing metabolic disorders |
| 04/23/2009 | WO2009013915A8 Inhibitor of plasminogen activator inhibitor-1 |
| 04/23/2009 | WO2008151170A3 Process for the synthesis of ramelteon and its intermediates |
| 04/23/2009 | WO2007009089A3 Compositions containing flammulina velutipes extracts and methods for their administration |
| 04/23/2009 | US20090105478 Novel compounds |
| 04/23/2009 | US20090105351 Micellar drug delivery systems for hydrophobic drugs |
| 04/23/2009 | US20090105350 Process for the preparation of atovaquone |
| 04/23/2009 | US20090105330 Admixture of carotenoids and isoflavonoids for treating cutaneous symptoms of aging |
| 04/23/2009 | US20090105312 Solid preparation having improved solubility |
| 04/23/2009 | US20090105291 Ethyl (2S)-2-[(4,4-dimethyl-3-oxo-1-cyclobutenyl)amino]-3-[(4-([2,7]naphthyridin-1-yloxy)phenyl]propanoate; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders |
| 04/23/2009 | US20090105243 for treating p38 kinase-associated conditions like inflammatory disorders; improved dissolution rate and oral bioavailability; rheumatic diseases; skin disorders; multiple sclerosis; osteoporosis; Alzheimer's disease |
| 04/23/2009 | US20090105229 Purine derivatives as kinase inhibitors |
| 04/23/2009 | US20090105222 Prevention and treatment of functional somatic disorders, including stress-related disorders |
| 04/23/2009 | US20090105204 Therapeutic Uses for Aminosterol Compounds |
| 04/23/2009 | US20090105197 Use of Sodium Channel Blocking Compounds and Aspirin in Manufacturing Drugs for Producing Analgesia Synergistically in Mammals |
| 04/23/2009 | US20090105172 Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics |
| 04/23/2009 | US20090105171 Methods for Regenerating and Repairing Damaged Tissues Using Adrenomedullin |
| 04/23/2009 | US20090105170 Multiple Heat Shock Elements |
| 04/23/2009 | US20090105167 Predicting responsiveness to cancer therapeutics |
| 04/23/2009 | US20090105150 Angiotensin derivatives |
| 04/23/2009 | US20090105140 Albumin Fusion Proteins |
| 04/23/2009 | US20090105137 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use |
| 04/23/2009 | US20090105116 Polypeptide Ligands Containing Linkers |
| 04/23/2009 | US20090104684 Diagnosis of carcinomas |
| 04/23/2009 | US20090104293 treating gastric ulcer with ginger extract nutraceuticals; gastrointestinal disorders |
| 04/23/2009 | US20090104290 Energizing formulation |
| 04/23/2009 | US20090104283 Method for reducing the severity of neurological disorders |
| 04/23/2009 | US20090104278 Food composition for recovery from fatigue |
| 04/23/2009 | US20090104263 5-HT4 partial agonist pharmaceutical compositions |
| 04/23/2009 | US20090104261 Treatment for Attention-Deficit Hyperactivity Disorder |
| 04/23/2009 | US20090104230 Compositions and methods of using capsid protein from flaviviruses and pestiviruses |
| 04/23/2009 | US20090104199 Breast Cancer Resistance Protein (BCRP) And The DNA Which Encodes It |
| 04/23/2009 | US20090104198 Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
| 04/23/2009 | US20090104196 for modulating the activity of the lysine-specific demethylase (LSD1) in a mammal; for identifying a patient having high risk prostate carcinomas |
| 04/23/2009 | US20090104182 Inhibition of tristetraproline for protection of the heart from cardiac injuries |
| 04/23/2009 | US20090104169 Pet food composition for skin photoprotection |
| 04/23/2009 | US20090104154 Composition and method for killing of tumours |
| 04/23/2009 | US20090104150 Polymer conjugates of interferon Beta-1a and uses |
| 04/23/2009 | CA2702958A1 Method for producing pyrazole fused ring derivative |
| 04/23/2009 | CA2702885A1 Pharmaceutical composition for treatment of cataract |
| 04/23/2009 | CA2702455A1 Therapeutic agent for trpv1-mediated disease |
| 04/23/2009 | CA2700910A1 Combination therapy for reducing side effects using cannabinoid receptor ligands |
| 04/22/2009 | EP2050762A2 Novel polypeptides and nucleic acids encoding the same |
| 04/22/2009 | EP2050751A1 Compounds specific to adenosine A1 and A3 receptors and uses thereof |
| 04/22/2009 | EP2050750A2 Multicyclic compounds and their use as inhibitors of PARP, VEGFR2 and MLK3 enzymes |
| 04/22/2009 | EP2050739A1 Quinazoline derivative |
| 04/22/2009 | EP2050468A1 Agent for treatment of cerebral ischemic diseases |
| 04/22/2009 | EP2050467A1 Therapeutic agent for amyotrophic lateral sclerosis |
| 04/22/2009 | EP2050466A1 Diagnosis and treatment of cancer using anti-desmoglein-3 antibody |
| 04/22/2009 | EP2050460A1 PYY and agonists thereof for modification of feeding behaviour |
| 04/22/2009 | EP2050453A1 Pharmaceutical combinations of meloxicam, tramadol and paracetamol |